6,119 SPDR S&P Biotech ETF $XBI Shares Acquired by Lyell Wealth Management LP

Lyell Wealth Management LP increased its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 22.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,000 shares of the exchange traded fund’s stock after buying an additional 6,119 shares during the period. Lyell Wealth Management LP’s holdings in SPDR S&P Biotech ETF were worth $5,203,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of XBI. Associated Banc Corp purchased a new position in shares of SPDR S&P Biotech ETF in the 3rd quarter valued at approximately $1,047,000. Integrity Alliance LLC. boosted its position in shares of SPDR S&P Biotech ETF by 16.2% during the third quarter. Integrity Alliance LLC. now owns 7,039 shares of the exchange traded fund’s stock valued at $1,110,000 after purchasing an additional 980 shares in the last quarter. GRIMES & Co WEALTH MANAGEMENT LLC boosted its position in shares of SPDR S&P Biotech ETF by 44.9% during the third quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 24,831 shares of the exchange traded fund’s stock valued at $3,915,000 after purchasing an additional 7,689 shares in the last quarter. BOCHK Asset Management Ltd bought a new stake in shares of SPDR S&P Biotech ETF during the third quarter valued at approximately $552,000. Finally, Signature Equity Partners LLC grew its stake in SPDR S&P Biotech ETF by 1,285.7% in the third quarter. Signature Equity Partners LLC now owns 194 shares of the exchange traded fund’s stock worth $31,000 after purchasing an additional 180 shares during the period.

SPDR S&P Biotech ETF Stock Up 1.9%

Shares of XBI stock opened at $154.97 on Wednesday. The business’s fifty day moving average is $156.14 and its 200 day moving average is $141.86. The stock has a market cap of $10.57 billion, a price-to-earnings ratio of 11.47 and a beta of 0.87. SPDR S&P Biotech ETF has a twelve month low of $106.30 and a twelve month high of $169.89.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.